中西医结合治疗急性髓系白血病疗效观察
|
摘要
目的：探讨中西医结合治疗方法对急性髓系白血病的临床疗效。
方法：采用回顾性资料分析方法,对20例初治急性髓系白血病患者病例资料进行临床疗效总结和研究对比,并根据治疗中是否使用中药将患者分为[中药+化疗组](简称治疗组)和[单纯化疗组](简称对照组)。观察诱导缓解期白血病患者的临床治疗效果,主要从临床疗效(完全缓解率、有效率、中医证候改善情况)；支持疗法(血制品输注均量、粒细胞集落刺激因子使用均量)；化疗药物毒副作用等方面进行观察对比,分析中药参与治疗后有无治疗优势?
结果：
1、两组完全缓解率及有效率分别为50%和60%,60%和70%,治疗组完全缓解率及有效率均低于对照组,经统计学检验,.两组数据无明显差异(P>0.05)。治疗组中医证候改善情况其症状量化积分明显减少,治疗前后积分比较存在统计学差异(P<0.05)。
2、化疗过程中两组患者均出现骨髓抑制,输注血制品方面,红细胞输注均量治疗组明显少于对照组,经比较有统计学差异(P<0.05),治疗组的血小板输注均量及粒细胞集落刺激因子使用均量少于对照组,经检验两组数据无统计学差异(P>0.05)。
3、化疗过程中出现副作用比较,其中肝损害发生率两组分别为30%和80%,治疗组明显低于对照组,经统计学检验,两组数据有明显差异(P<0.05)。
结论：
1．中西医结合治疗急性髓系白血病,中药在支持疗法中显示出一定优势,可以减少患者的输血用量；在刺激骨髓恢复正常造血功能方面,中药具体作用机制本项研究尚无法确定,有待于积累更多的病例资料和开展相关实验研究进一步观察验证.
2.中药在减轻化疗药物的毒副作用方面初见端倪,本项研究显示中药可减少化疗药物肝损害的发生率；对心脏和肾脏有无保护作用由于本项研究样本数太小、观察周期较短,目前尚无结果,有待于进一步观察。
3.中药参与治疗在提高白血病CR率方面有无优势?本项研究尚不能确定。
Objective:To investigate the efficacy of the combined treatment of traditional Chinese Medicine (TCM) and western medicine for acute myelogenous leukemia (AML)
Methods:The method of retrospective statistical analysis was employed here to study 20 patients with AML to make clinic data summary and comparison. The patients were separated into two groups, the Chinese medicine-chemotherapy group (also called treatment group) and the chemotherapy group (also called control group) according to the use of Chinese traditional medicine during the treatment. To observe the efficacy of remission induction therapy and to make comparison mainly from the aspects of clinical efficacy (complete remission rate, efficacy and TCM symptomatic improvement); supportive treatment (both the average amount of blood products transfusion and granulocyte colony-stimulating factor being used) and the chemotherapy side effects. Analyze the advantages of participation of traditional Chinese medicine.
Results:1. The complete remission rates and effective rates of the two groups are 50% and 60%,60% and70%, and we could see that the complete remission rate and effective rate of treatment group are inferior to the control group, and there were no significant differences between the two sets of data according to statistical tests. (P>0.05) The symptomatic improvement and the quantization points significantly reduced and there was significant differences before and after the treatment (P<0.05).
2. During the chemotherapy, bone marrow suppression could be seen in both groups of patients; the treatment group was inferior to the control group in the average amount of blood transfusion during the chemotherapy and there were significant difference between the two groups (P<0.05); the treatment group was inferior to the control group in the G-CSF and platelet transfusion average volumes and there were no significant differences between the two groups (P>0.05)
3. To compare the side effects during the chemotherapy. The incidences of hepatic damage of the two groups are 30% and 80% respectively, from which we could see the incidence of treatment group is much lower than that of the control group and there was significant difference (P< 0.05)
Conclusion:1. During the combined treatment of traditional Chinese Medicine and western medicine for acute leukemia, Chinese medicine shows some advantages in decreasing the blood transfusion. But we don't know whether it has advantages in stimulating the recovery of the hematopoiesis, which needs more clinical experiences and intensive observation and verification.
2. The efficacy of Chinese medicine in reducing the toxic side effects of chemotherapy drugs began to be seen. This study shows traditional Chinese medicine can reduce the incidence of liver damage of chemotherapy. We can't conclude about whether the Chinese medicine has protection effects on heart and kidneys from this study because the sample size was small and the observation period was short.
3. The advantage of Chinese medicine in improve the CR rate of leukemia requires further study.
方法：采用回顾性资料分析方法,对20例初治急性髓系白血病患者病例资料进行临床疗效总结和研究对比,并根据治疗中是否使用中药将患者分为[中药+化疗组](简称治疗组)和[单纯化疗组](简称对照组)。观察诱导缓解期白血病患者的临床治疗效果,主要从临床疗效(完全缓解率、有效率、中医证候改善情况)；支持疗法(血制品输注均量、粒细胞集落刺激因子使用均量)；化疗药物毒副作用等方面进行观察对比,分析中药参与治疗后有无治疗优势?
结果：
1、两组完全缓解率及有效率分别为50%和60%,60%和70%,治疗组完全缓解率及有效率均低于对照组,经统计学检验,.两组数据无明显差异(P>0.05)。治疗组中医证候改善情况其症状量化积分明显减少,治疗前后积分比较存在统计学差异(P<0.05)。
2、化疗过程中两组患者均出现骨髓抑制,输注血制品方面,红细胞输注均量治疗组明显少于对照组,经比较有统计学差异(P<0.05),治疗组的血小板输注均量及粒细胞集落刺激因子使用均量少于对照组,经检验两组数据无统计学差异(P>0.05)。
3、化疗过程中出现副作用比较,其中肝损害发生率两组分别为30%和80%,治疗组明显低于对照组,经统计学检验,两组数据有明显差异(P<0.05)。
结论：
1．中西医结合治疗急性髓系白血病,中药在支持疗法中显示出一定优势,可以减少患者的输血用量；在刺激骨髓恢复正常造血功能方面,中药具体作用机制本项研究尚无法确定,有待于积累更多的病例资料和开展相关实验研究进一步观察验证.
2.中药在减轻化疗药物的毒副作用方面初见端倪,本项研究显示中药可减少化疗药物肝损害的发生率；对心脏和肾脏有无保护作用由于本项研究样本数太小、观察周期较短,目前尚无结果,有待于进一步观察。
3.中药参与治疗在提高白血病CR率方面有无优势?本项研究尚不能确定。
Objective:To investigate the efficacy of the combined treatment of traditional Chinese Medicine (TCM) and western medicine for acute myelogenous leukemia (AML)
Methods:The method of retrospective statistical analysis was employed here to study 20 patients with AML to make clinic data summary and comparison. The patients were separated into two groups, the Chinese medicine-chemotherapy group (also called treatment group) and the chemotherapy group (also called control group) according to the use of Chinese traditional medicine during the treatment. To observe the efficacy of remission induction therapy and to make comparison mainly from the aspects of clinical efficacy (complete remission rate, efficacy and TCM symptomatic improvement); supportive treatment (both the average amount of blood products transfusion and granulocyte colony-stimulating factor being used) and the chemotherapy side effects. Analyze the advantages of participation of traditional Chinese medicine.
Results:1. The complete remission rates and effective rates of the two groups are 50% and 60%,60% and70%, and we could see that the complete remission rate and effective rate of treatment group are inferior to the control group, and there were no significant differences between the two sets of data according to statistical tests. (P>0.05) The symptomatic improvement and the quantization points significantly reduced and there was significant differences before and after the treatment (P<0.05).
2. During the chemotherapy, bone marrow suppression could be seen in both groups of patients; the treatment group was inferior to the control group in the average amount of blood transfusion during the chemotherapy and there were significant difference between the two groups (P<0.05); the treatment group was inferior to the control group in the G-CSF and platelet transfusion average volumes and there were no significant differences between the two groups (P>0.05)
3. To compare the side effects during the chemotherapy. The incidences of hepatic damage of the two groups are 30% and 80% respectively, from which we could see the incidence of treatment group is much lower than that of the control group and there was significant difference (P< 0.05)
Conclusion:1. During the combined treatment of traditional Chinese Medicine and western medicine for acute leukemia, Chinese medicine shows some advantages in decreasing the blood transfusion. But we don't know whether it has advantages in stimulating the recovery of the hematopoiesis, which needs more clinical experiences and intensive observation and verification.
2. The efficacy of Chinese medicine in reducing the toxic side effects of chemotherapy drugs began to be seen. This study shows traditional Chinese medicine can reduce the incidence of liver damage of chemotherapy. We can't conclude about whether the Chinese medicine has protection effects on heart and kidneys from this study because the sample size was small and the observation period was short.
3. The advantage of Chinese medicine in improve the CR rate of leukemia requires further study.
引文
1 张伟玲,严鲁萍.急性白血病中医病因病机探讨.河南中医,2009,29(5)：433-434.
2 赵为疗急性白血病体会.河南中医,2007,27(4)：75-76.
3 史大卓,马晓昌主编.常见难治病中西医结合治疗.北京：新世纪出版社,1992.604-607-6121.
4 谢文武,刘晓春.急性白血病病因及防治探讨.黑龙江中医,2003,2：5-6.
5 胡青山,孙伟正.中医药学报,Acta Chinese Medicine and Pharmacology, 1978, S1:37-38.
6 赵绍琴.赵绍琴临床经验辑要.北京：中国医药科技出版社,2001.84-88.
7 梁冰,葛志红.《血液科专病中医临床诊治》第2版.北京：人民卫生出版社,2005.1.
8 杨金坤.《现代中医肿瘤学》上海：上海中医药大学出版社,2004.7.
9 罗秀素.急性白血病辨治体会.中国中医急症,2003,12(3)：280～281.
10 谢天亮.白血病的中医论治.基层医学论坛2008,12(11)：1018-1019.
11 孙鸿德.白血病辨证经验谈.黑龙江中医药,1984,(6)：58.
12 李俊辉.中西医结合治疗急性白血病98例.中医杂志,1987,(3)：65.
13 李富生.常见病中医临床治疗进展.北京：中国中医药出版社,1991.358～359,366.
14 王介入.常见病中医临床治疗进展.北京：中国中医药出版社,1991.367.
15 周国雄.白血病分型治疗.中医杂志,1983,(6)：239.
16 王天恩,王尚平.中医对急性白血病的认识.北京中医药大学学报,1996,19(6)：54-55.
17 周霭祥.中药治疗白血病体会.新医药学杂志,1978,(11)：58-61.
18 梁冰.中西医集合治疗白血病体会.中医杂志,1985,(10)：13.
19 吴翰香.辨证治疗白血病.中医杂志,1985,(10)：27.
20.曹芳,李彦,贾斌等,唐由君治疗急性血液病的经验.国医论坛,2001,16(2)：11-12.
21 邓有安.活血化瘀中药加抗癌药治疗急性白血病近期疗效观察.中西医结合杂志,1998,8(11)：683.
22 王继亮.急性白血病辨证治疗体会.河北中医杂志,1996,1(1)：1-2.
23 马明.中西医结合治疗急性白血病临床体会.吉林中医药,1995,(1)：8.
24 周国雄.龙胆泻肝汤加减治疗急性白血病26例临床观察.中医杂志,1980,(4)：38.
25 王镜.中西医结合治疗白血病疗效分析.中医杂志,1983,(12)：26.
26 王锦丽,刘晓妹,张全.中西医结合治疗老年急性非淋巴细胞白血病30例. 陕西中医,1999,20(2)：53.
27 唐由君.白血病辨证分型与某些客观指标的观察.上海中医药杂志,1991,(8)：4.
28 李仝,马鸣飞.中医药在造血干细胞移植治疗急性白血病中的应用体会.中国医药学报,2002,17(2)：101-104.
29 李海燕,钱林生,薛艳萍等.中医药在急性白血病化疗中作用的探讨.中国中西医结合杂志,1995,15(10)：628-629.
30 徐瑞荣,顾振东,焦中华等.157例急性白血病化疗毒副作用的中医辨证治疗.上海中医药杂志,1993,7：7-9.
31 朱玲玲.养正汤减轻急性白血病化疗后毒副作用疗效观察.新中医,1999,31(3)：27-28
32 马明.中药防治急性白血病化疗毒副反应.浙江中医杂志,1997,8(4)：343-344
33 刘峰,麻柔.血液病学.北京：.中国中医药出版社,1998.238-247
34 陈明校.单用六神丸治疗成人急性白血病.中西医结合杂志,1989,9(12)：719.
35 孙鸿德.癌灵1号结合中医辨证治疗急性早幼粒细胞白血病32例.中西医结合杂志,1992,12(3)：170.
36 黄土林.中药白血康为主治疗早幼粒细胞白血病的临床研究.中华血液学会第八届全国白血病学术会议资料汇编,1995.41.
37 唐由君.传统抗癌中成药配合中药复方治疗白血病的研究.中国中西医结合杂志,1998,18(10)：583.
38 张晨,黄世林,向阳.低剂量雄黄诱导NB4细胞凋亡的研究.中国中医基础医学杂志,2000,6(2)：11.
39 于志峰,戴锡盂,戴锡珍.益气养阴清热解毒法治疗微小残留白血病的凋亡机制研究.天津中医,2001,18(4)：29.
40 高顺利,王听,陈信义.益髓灵兔血清诱导HL-60细胞凋亡与对bcl-2抑制研究.中国中医基础医学杂志,2000,6(8)：27.
41 李振波,丘和明,刘国普.清毒饮和养正片对环磷酰胺所致的造血抑制小鼠粒系造血的影响.广州中医药大学学报,1999,16(1)：34.
42 李振波,丘和明,张萍.L7212白血病小鼠IL-2活性、IL-2mRNA表达及复方中药清毒饮对其影响的研究.中国免疫学杂志,2000,16(1)；25.
43 张洪钧,陈信义,孙颖立.清热养阴药作用后的脐血细胞浆逆转白血病细胞表型研究.北京中医药大学学报,2000,23(5)：42-47.
44 王锦丽,武艳敏,贾月莉.血瘀型急性髓细胞白血病与淋巴细胞分化抗原关系的临床研究.中西医结合实用临床急救,1997,4(8)：357-358.
45 苏伟,李伟.急性白血病中医证候分型与P170表达及临床疗效关系的研究.北京中医药大学学报,2001,24(2)；55-57.
46 林圣云,罗秀素,胡致平等.急性非淋巴细胞白血病辨证与细胞遗传学变化的 关系.江西中医药,1998,29(4)；20～21.
47 Varma MV, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening:a perspective from bioavailability enhancement. Pharmacol Res,2003,48 (4):347.
48 Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc),2000,65(1):95.
49 Sarqent JM, Elqie AW, Williamson CJ, et al. Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML. Adv Exp Med Biol,1999,457:567.
50 Di Simone D, Testi R, Caracciolo F, et al. Glutathiong-Stransferase activity and multidrug resistance bhenotype in chronic lymphocytic leukemia:Do they have any clinicalrelevance? Haematoloqica,1995,80 (2):103.
51 Lohri A, van Hille B, Bacchi M, et al. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione S-transferase, bc1-2 and topoisomerase Ⅱalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK). Eur J Haematol,1997,59 (4):206.
52 许文林,敖忠芳,陈宝安等.汉防已甲素逆转血液系统肿瘤细胞多药耐药的临床研究.中华内科杂志,2001,40(9)：631.
53 Chen GQ, Zhu J, Shi XG, et al. In vitro studies on celluar and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia:As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood,1996,88 (3):1052.
54 苏颖,邹长棪,陈增等.三氧化二砷及干扰素联用对K562及K562/ADM耐药细胞系的作用.福建医科大学学报,2003,37(2)：155.
55 郭娟娟, 潘祥林, 冯长伟等.冬凌草甲素诱导多药耐药细胞系K562／A02凋亡、逆转耐药性的研究.安徽中医学院学报,2000,19(3)：34.
56 汤涛,蒙凌华,陈凌际等.鸦胆子油乳具有多药耐药逆转和拓扑异构酶Ⅱ抑制作用.中国药理学通报,2001,17(5)：534.
57 于丽君,孔力.蝎毒对MCF-7/ADM细胞GST-JI表达的研究.中医药学刊,2003,21(7)：1107[12]贾莉,孔力,苗小艳等.蝎毒逆转K562/ADM细胞多药耐药性的初步研究.白血病·淋巴瘤,2002,11(2)：81.
58 李炳生,陈秀华,任文龙等.康莱特注射液的抗肿瘤作用.中国医药工业杂志,1998,29(10)：456.
59 董庆华,郑树,吕庆华.康莱特注射液对多药耐药人白血病细胞株作用的实验研究.实用肿瘤杂志,2002,17(1)：24.
60 梁蓉,杨平地,陈协群.川芎嗪和(或)环孢素A对HL60/HT细胞耐药的逆转.中华内科杂志,1999,38(4)：260.
61 高船舟,杨佩满,吕广艳等.20(R)-人参皂甙Rg3逆转K562/ADM细胞MDR及诱导其凋亡的研究.解剖科学进展,2002,8(1)：31.
62 蔡宇,曹克俭,殷忠东.补骨脂素胶囊对急性白血病多药耐药逆转作用的临床观察.中国中医药科技,2002,9(1)：53.
63 Kondratov RV, Komarov PG, Becker Y, et al. Small molecules that dramatically after multidrug resistance phenotype by modulating the substrate specificity of P-glycoporotein. Proc Natl Acad Sci U S A, 2001,98 (24):14078.
64 Leslie EM, Mao Q, Oleschuk CJ, et al. Modulation of multidrug resistance protein 1 (MRP/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol,2001,59 (5):1171.
65 谢长生,周维顺,郭勇等.三根制剂对MDR细胞株逆转的研究.实用中医药杂志,2003,19(3)：115.
66 贾菊芳,敖明章,胡本容等.甲基莲心碱对脂质过氧化和活性氧自由基的作用.同济医科大学学报,1994,23(1)：62.
67 林秀梅,谢兆霞,秦群.甲基莲心碱、红霉素逆转K562／A02细胞多药耐药及机制的研究.中华血液学杂志,2005,26(5)：305.
68 肖希斌,谢兆霞,秦群.甲基莲心碱抑制K562／A02细胞GST-π的表达.西安交通大学学报(医学版),2005,26(5)：428.
69 孔平孝,陈光伟,王希胜等.天佛参口服液治疗中晚期恶性肿瘤的临床与实验研究.中国中西医结合杂志,2001,21(6)：427.
70 杨国武,党琦,李新民.天佛参逆转K562/ADM细胞株耐药性的作用及机制探讨.现代中西医结合杂志,2002,11(19)：1865.
71 Liang G, Zhang S, Huang ZM, et al. MDR-reversing effect of two components of catechin on human hepatocellular carcinoma BEL-7404/Adr in vitro. Ai Zheng,2004,23 (4):401.
72 赵芳, 张茂宏, 李丽珍, 等.环孢菌素A联合表没食子儿茶素没食子酸酯逆转白血病多药耐药的体外研究.中华血液学杂志,2005,26(8)：502
73 Fan CW, Chan CC, Chao CC, et al. Expression patterns of cell cycle and apoptosis-related genes in a multidrug-resistant human colon carcinoma cell line. Scand J Gastroenterol,2004,39 (5):464.
74 杨岚,杨平地,梁蓉等.川芎嗪联合环胞霉素A逆转白血病多药耐药的研究.癌症,2000,19(4)：304.
75 陈宝安,盛茗,高峰等.联合应用汉防已甲素和他莫西芬逆K562/VCR细胞株多药耐药.白血病-淋巴瘤,2001,10(2)：71.
76 陈宝安,董颖,张鹏等.汉防已甲素联合屈洛昔芬逆转K562／A02细胞多药耐 药的研究.中华血液学杂志,2002,23(12)：660.
77 梁蓉,杨平地,陈协群.川芎嗪和异博定联合逆转HL60/HT细胞的多药耐药.第四军医大学学报,1998,19(4)：385.
78 TallmanMS. New strategies for the treatment of acute myeloid leukemia including antibodies and other lovel agents [J].Hematology,2005,10: 143-150.
79 Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML:analysis of 1,612 patients entered into the MRC AML 10 trial The Medical Research CouncilAdult and Children's LeukaemiaWork2ing Parties [J].Blood,1998,92:2322-2333.
80 Stone RM, ODonnellMR, SekeresMA. Acute myeloid leukemia [J]. Hematology, 2004,9:98-117.
81 SlovakML, Kopecky KJ, Cassileth PA, et al.Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:a Southwest Oncology Group/Eastern Cooperative Oncology Group Study [J].Blood,2000,96:4075-4083.
82 SanzMA, Martin G, GonzalezM, et al.Risk-adapted treamtment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:a multicenter study by the PETHEMA group [J]. Blood, 2004,103:1237-1243.
83 Rowe JM,Neuberg D,FriedenbergW, et al. A phase 3 study of three induction regimens and of p riming with GM2CSF in older adultswith acutemyeloid leukemia:a trial by the Eastem Cooperative Oncology Group [J].Blood, 2004,103:479-485.
84 Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patientswith acute myeloid leukemia is not imp roved with mitoxantrone and etoposide compared to cytarabine and daunorubicin:a SouthwestOncology Group study[J]. Blood,2002,100: 3869-3876.
85 Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group [J].N Engl J Med,1994,331:896-903.
86 Meloni G, Diverio D, VignettiM, et al. Autologous bone marrow transp lantation for acute promyelocytic leukemia in second remission:prognostic relevance of pretransp lantminimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene [J]. Blood,1997,90:1321-1325.
87 Linker CA, Ries CA, Damon LE, et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission[J]. Biol BloodMarrow Transplant,2000,6:50-57.
88 Suciu S, Mandelli F, de-Witte T, et al.Allogeneic compared with autologous stem cell transp lantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first comp lete remission (CR1):an intention-to-treat analysis of the EORTC/GIMEMAAML210 trial [J]. Blood,2003,102:1232-1240.
89 Zittoun RA, Mandelli F, Willemze R, et al.Autologous or allo-geneic bone marrow transp lantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Group s[J]. N Engl J Med, 1995,332:217-223.
90 Cornelissen JJ, Lowenberg B.Role of allogeneic stem cell transplantation on current treatment of acute myeloid leukemia[J]. Hematology,2005,10:151-155.
91 Sievers EL, Larson RA, Stadtmauer EA, et al.Efficacy and safety of gemtuzumab ozogamicin in patientswith CD332positive acute myeloid leukemia in first relapse [J]. J Clin On-col,.2001,19:3244-3254.
92 Amadori S, Suciu S, Stasi R, Willemze R, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and olderwith acutemyeloid leukemia:final results of AML215B, a phase-study of the European Organisation for Research and Treatment of Cancer and Gruppo ItalianoMalattie Ematologiche dell'Adulto Leukemia Groups [J]. Leukemia,2005,19:1768-1773.
93 KellWJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia [J]. Blood,2003,102:4277-4283.
94 沈志祥主编.难治性血液系统疾病[M].上海：上海科学技术出版社.2007：135-161.
95 Nikanfar A.Asvadi I, VN(?)J. Mitoxantrone plus cytarabine versus daunorubicin plus cytaxabine as induetion therapy for previously untreated adult patients with acute myeloid leukemia[J]. Pakistan Journal of Medical Sciences.2007.23:909-912
96 Preisler HD, Davis RB, Kirshner J, Dupre E, Richards FM, Hoagland HC et al. Comparison of three remission induction regimens and two post induction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood 1987; 69:1441-1449.
97 Cooper T, Agm M, Nowak B, at al. Biochemical modulation Of eytarabine triphosphate by elofarabinelJ]. Cancer Chemother Phannaeol,2005.55: 361-368.
98 Mustn P. Ferrara F.Clofarabine:in search of combinations for the treatment of patients with Mgh-risk acute myeloid leukemia[J].Caner2008: 1995-1998.
99 王千山等.30例大剂量阿糖胞苷化疗毒副作用的临床观察.药物与临床,2006,3(3)：8.
100 周爱萍,王奇璐.抗肿瘤药物对消化系统不良反应及其防治[J].实用肿瘤杂志,2002,17(2)：792811
101 张之南,沈悌.《血液病诊断及疗效标准(第三版)》.北京：科学技术出版社.2007.1.
102 郑筱萸.《中药新药临床研究指导原则》.北京：中国医药科技出版社.2002.4.
103 陈灏珠.《实用内科学》12版.北京：人民卫生出版社.2005.5.
104 楼金星等.强化治疗对急性早幼粒细胞白血病长期生存的影响.实用医学杂志,2007,23(21)：3389-3391.
105 吴光启等.米托蒽醌联合阿糖胞苷治疗急性粒细胞白血病36例疗效观察.中国煤炭工业医学杂志,2001,4(6).458-459.
106 郑君议等.米托蒽醌联合阿糖胞苷诱导治疗成人初治急性髓细胞性白血病疗效分析.重庆医学,2005,34(9)：1301-1304.
107 夏学鸣等.米托蒽醌联合阿糖胞苷方案治疗急性非淋巴细胞白血病52例疗效观察.江苏医药,2001,27(4)：309.
108 李梅君等.米托蒽醌和阿糖胞苷方案治疗急性非淋巴细胞白血病30例.医学综述,2009,15(18)：2867-2868.
109 李静等.MA与HDA方案治疗急性髓细胞白血病的近期疗效比较.安徽医学,2003,24(6)：57-58.
110 王璇等.MA与DA方案诱导缓解急性非淋巴细胞白血病的临床观察.中国现代医学杂志,2008,18(14)：2072-2077.
111 秦彦等.MA与DA方案诱导缓解急性单核细胞白血病的疗效比较.山西医药杂志,2009,38(8)：743-745.
112 周凡等.MA和DA方案治疗急性髓系白血病疗效对比分析.中国误诊学杂志,2005,5(3)：512-513.
113 宋东晓.MA和DA方案治疗急性非淋巴细胞白血病疗效比较.山东医药,2002,42(17)：23-24.
114 郭新红等.MA和DA方案治疗初治急性非淋巴细胞白血病的疗效分析.新疆医学,2006,36(2)：89-90.
115 艾丽梅等.MA和DA方案治疗成人急性髓细胞性白血病疗效观察.中国医药导 报,2007,4(3)：32-33.
116 李碧玲等.MA和DA方案治疗成人急性髓细胞白血病疗效分析.白血病·淋巴瘤,2004,13(4)：237-238.
117 赵璐.MA和DA方案治疗成人急性髓细胞白血病疗效比较.中国医师进修杂志,2007,30(13)：63-64.
118 赖永榕等.MA方案与ID-Ara-C方案治疗难治性及复发性急性髓细胞性白血病疗效观察.临床内科杂志,1999,16(1)
119 沈益民等.MA方案与DA、HA方案治疗复发性急性白血病的比较研究.临床荟萃,1998,13(22)：1034-1035
120 罗绍凯等.DA与MA方案诱导缓解急性非淋巴细胞白血病的疗效比较.新医学,2003,34(9)：549-553.
121 高学熙等.DA和MA方案治疗急性髓细胞性白血病疗效比较.白血病,1997,7(3)：165-166.
122 严峰.DA-MA序贯疗法治疗累及单核细胞的急性白血病疗效观察.白血病·淋巴瘤,2004,13(2)：109-110.
123 姜红,张秋业,黄芪对新生儿脐血Thl/Th2功能平衡的影响.中华围产医学杂志,2003,6(4)：225
124 贾泰元,党参对鼠J774巨噬细胞吞噬活性的增强效应.时珍国医国药,2000,11(9)：769.
125 雷载权,中药学.上海科学出版社,1995：132-311.
126 彭新国,邱世翠,李彩玉,白术对小鼠免疫功能影响的实验研究.时珍国医国药,2001,12(5)：396.
127 李佩文.中西医临床肿瘤学.北京：中国中医药出版社,1996.12.
2 赵为疗急性白血病体会.河南中医,2007,27(4)：75-76.
3 史大卓,马晓昌主编.常见难治病中西医结合治疗.北京：新世纪出版社,1992.604-607-6121.
4 谢文武,刘晓春.急性白血病病因及防治探讨.黑龙江中医,2003,2：5-6.
5 胡青山,孙伟正.中医药学报,Acta Chinese Medicine and Pharmacology, 1978, S1:37-38.
6 赵绍琴.赵绍琴临床经验辑要.北京：中国医药科技出版社,2001.84-88.
7 梁冰,葛志红.《血液科专病中医临床诊治》第2版.北京：人民卫生出版社,2005.1.
8 杨金坤.《现代中医肿瘤学》上海：上海中医药大学出版社,2004.7.
9 罗秀素.急性白血病辨治体会.中国中医急症,2003,12(3)：280～281.
10 谢天亮.白血病的中医论治.基层医学论坛2008,12(11)：1018-1019.
11 孙鸿德.白血病辨证经验谈.黑龙江中医药,1984,(6)：58.
12 李俊辉.中西医结合治疗急性白血病98例.中医杂志,1987,(3)：65.
13 李富生.常见病中医临床治疗进展.北京：中国中医药出版社,1991.358～359,366.
14 王介入.常见病中医临床治疗进展.北京：中国中医药出版社,1991.367.
15 周国雄.白血病分型治疗.中医杂志,1983,(6)：239.
16 王天恩,王尚平.中医对急性白血病的认识.北京中医药大学学报,1996,19(6)：54-55.
17 周霭祥.中药治疗白血病体会.新医药学杂志,1978,(11)：58-61.
18 梁冰.中西医集合治疗白血病体会.中医杂志,1985,(10)：13.
19 吴翰香.辨证治疗白血病.中医杂志,1985,(10)：27.
20.曹芳,李彦,贾斌等,唐由君治疗急性血液病的经验.国医论坛,2001,16(2)：11-12.
21 邓有安.活血化瘀中药加抗癌药治疗急性白血病近期疗效观察.中西医结合杂志,1998,8(11)：683.
22 王继亮.急性白血病辨证治疗体会.河北中医杂志,1996,1(1)：1-2.
23 马明.中西医结合治疗急性白血病临床体会.吉林中医药,1995,(1)：8.
24 周国雄.龙胆泻肝汤加减治疗急性白血病26例临床观察.中医杂志,1980,(4)：38.
25 王镜.中西医结合治疗白血病疗效分析.中医杂志,1983,(12)：26.
26 王锦丽,刘晓妹,张全.中西医结合治疗老年急性非淋巴细胞白血病30例. 陕西中医,1999,20(2)：53.
27 唐由君.白血病辨证分型与某些客观指标的观察.上海中医药杂志,1991,(8)：4.
28 李仝,马鸣飞.中医药在造血干细胞移植治疗急性白血病中的应用体会.中国医药学报,2002,17(2)：101-104.
29 李海燕,钱林生,薛艳萍等.中医药在急性白血病化疗中作用的探讨.中国中西医结合杂志,1995,15(10)：628-629.
30 徐瑞荣,顾振东,焦中华等.157例急性白血病化疗毒副作用的中医辨证治疗.上海中医药杂志,1993,7：7-9.
31 朱玲玲.养正汤减轻急性白血病化疗后毒副作用疗效观察.新中医,1999,31(3)：27-28
32 马明.中药防治急性白血病化疗毒副反应.浙江中医杂志,1997,8(4)：343-344
33 刘峰,麻柔.血液病学.北京：.中国中医药出版社,1998.238-247
34 陈明校.单用六神丸治疗成人急性白血病.中西医结合杂志,1989,9(12)：719.
35 孙鸿德.癌灵1号结合中医辨证治疗急性早幼粒细胞白血病32例.中西医结合杂志,1992,12(3)：170.
36 黄土林.中药白血康为主治疗早幼粒细胞白血病的临床研究.中华血液学会第八届全国白血病学术会议资料汇编,1995.41.
37 唐由君.传统抗癌中成药配合中药复方治疗白血病的研究.中国中西医结合杂志,1998,18(10)：583.
38 张晨,黄世林,向阳.低剂量雄黄诱导NB4细胞凋亡的研究.中国中医基础医学杂志,2000,6(2)：11.
39 于志峰,戴锡盂,戴锡珍.益气养阴清热解毒法治疗微小残留白血病的凋亡机制研究.天津中医,2001,18(4)：29.
40 高顺利,王听,陈信义.益髓灵兔血清诱导HL-60细胞凋亡与对bcl-2抑制研究.中国中医基础医学杂志,2000,6(8)：27.
41 李振波,丘和明,刘国普.清毒饮和养正片对环磷酰胺所致的造血抑制小鼠粒系造血的影响.广州中医药大学学报,1999,16(1)：34.
42 李振波,丘和明,张萍.L7212白血病小鼠IL-2活性、IL-2mRNA表达及复方中药清毒饮对其影响的研究.中国免疫学杂志,2000,16(1)；25.
43 张洪钧,陈信义,孙颖立.清热养阴药作用后的脐血细胞浆逆转白血病细胞表型研究.北京中医药大学学报,2000,23(5)：42-47.
44 王锦丽,武艳敏,贾月莉.血瘀型急性髓细胞白血病与淋巴细胞分化抗原关系的临床研究.中西医结合实用临床急救,1997,4(8)：357-358.
45 苏伟,李伟.急性白血病中医证候分型与P170表达及临床疗效关系的研究.北京中医药大学学报,2001,24(2)；55-57.
46 林圣云,罗秀素,胡致平等.急性非淋巴细胞白血病辨证与细胞遗传学变化的 关系.江西中医药,1998,29(4)；20～21.
47 Varma MV, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening:a perspective from bioavailability enhancement. Pharmacol Res,2003,48 (4):347.
48 Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc),2000,65(1):95.
49 Sarqent JM, Elqie AW, Williamson CJ, et al. Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML. Adv Exp Med Biol,1999,457:567.
50 Di Simone D, Testi R, Caracciolo F, et al. Glutathiong-Stransferase activity and multidrug resistance bhenotype in chronic lymphocytic leukemia:Do they have any clinicalrelevance? Haematoloqica,1995,80 (2):103.
51 Lohri A, van Hille B, Bacchi M, et al. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione S-transferase, bc1-2 and topoisomerase Ⅱalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK). Eur J Haematol,1997,59 (4):206.
52 许文林,敖忠芳,陈宝安等.汉防已甲素逆转血液系统肿瘤细胞多药耐药的临床研究.中华内科杂志,2001,40(9)：631.
53 Chen GQ, Zhu J, Shi XG, et al. In vitro studies on celluar and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia:As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood,1996,88 (3):1052.
54 苏颖,邹长棪,陈增等.三氧化二砷及干扰素联用对K562及K562/ADM耐药细胞系的作用.福建医科大学学报,2003,37(2)：155.
55 郭娟娟, 潘祥林, 冯长伟等.冬凌草甲素诱导多药耐药细胞系K562／A02凋亡、逆转耐药性的研究.安徽中医学院学报,2000,19(3)：34.
56 汤涛,蒙凌华,陈凌际等.鸦胆子油乳具有多药耐药逆转和拓扑异构酶Ⅱ抑制作用.中国药理学通报,2001,17(5)：534.
57 于丽君,孔力.蝎毒对MCF-7/ADM细胞GST-JI表达的研究.中医药学刊,2003,21(7)：1107[12]贾莉,孔力,苗小艳等.蝎毒逆转K562/ADM细胞多药耐药性的初步研究.白血病·淋巴瘤,2002,11(2)：81.
58 李炳生,陈秀华,任文龙等.康莱特注射液的抗肿瘤作用.中国医药工业杂志,1998,29(10)：456.
59 董庆华,郑树,吕庆华.康莱特注射液对多药耐药人白血病细胞株作用的实验研究.实用肿瘤杂志,2002,17(1)：24.
60 梁蓉,杨平地,陈协群.川芎嗪和(或)环孢素A对HL60/HT细胞耐药的逆转.中华内科杂志,1999,38(4)：260.
61 高船舟,杨佩满,吕广艳等.20(R)-人参皂甙Rg3逆转K562/ADM细胞MDR及诱导其凋亡的研究.解剖科学进展,2002,8(1)：31.
62 蔡宇,曹克俭,殷忠东.补骨脂素胶囊对急性白血病多药耐药逆转作用的临床观察.中国中医药科技,2002,9(1)：53.
63 Kondratov RV, Komarov PG, Becker Y, et al. Small molecules that dramatically after multidrug resistance phenotype by modulating the substrate specificity of P-glycoporotein. Proc Natl Acad Sci U S A, 2001,98 (24):14078.
64 Leslie EM, Mao Q, Oleschuk CJ, et al. Modulation of multidrug resistance protein 1 (MRP/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol,2001,59 (5):1171.
65 谢长生,周维顺,郭勇等.三根制剂对MDR细胞株逆转的研究.实用中医药杂志,2003,19(3)：115.
66 贾菊芳,敖明章,胡本容等.甲基莲心碱对脂质过氧化和活性氧自由基的作用.同济医科大学学报,1994,23(1)：62.
67 林秀梅,谢兆霞,秦群.甲基莲心碱、红霉素逆转K562／A02细胞多药耐药及机制的研究.中华血液学杂志,2005,26(5)：305.
68 肖希斌,谢兆霞,秦群.甲基莲心碱抑制K562／A02细胞GST-π的表达.西安交通大学学报(医学版),2005,26(5)：428.
69 孔平孝,陈光伟,王希胜等.天佛参口服液治疗中晚期恶性肿瘤的临床与实验研究.中国中西医结合杂志,2001,21(6)：427.
70 杨国武,党琦,李新民.天佛参逆转K562/ADM细胞株耐药性的作用及机制探讨.现代中西医结合杂志,2002,11(19)：1865.
71 Liang G, Zhang S, Huang ZM, et al. MDR-reversing effect of two components of catechin on human hepatocellular carcinoma BEL-7404/Adr in vitro. Ai Zheng,2004,23 (4):401.
72 赵芳, 张茂宏, 李丽珍, 等.环孢菌素A联合表没食子儿茶素没食子酸酯逆转白血病多药耐药的体外研究.中华血液学杂志,2005,26(8)：502
73 Fan CW, Chan CC, Chao CC, et al. Expression patterns of cell cycle and apoptosis-related genes in a multidrug-resistant human colon carcinoma cell line. Scand J Gastroenterol,2004,39 (5):464.
74 杨岚,杨平地,梁蓉等.川芎嗪联合环胞霉素A逆转白血病多药耐药的研究.癌症,2000,19(4)：304.
75 陈宝安,盛茗,高峰等.联合应用汉防已甲素和他莫西芬逆K562/VCR细胞株多药耐药.白血病-淋巴瘤,2001,10(2)：71.
76 陈宝安,董颖,张鹏等.汉防已甲素联合屈洛昔芬逆转K562／A02细胞多药耐 药的研究.中华血液学杂志,2002,23(12)：660.
77 梁蓉,杨平地,陈协群.川芎嗪和异博定联合逆转HL60/HT细胞的多药耐药.第四军医大学学报,1998,19(4)：385.
78 TallmanMS. New strategies for the treatment of acute myeloid leukemia including antibodies and other lovel agents [J].Hematology,2005,10: 143-150.
79 Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML:analysis of 1,612 patients entered into the MRC AML 10 trial The Medical Research CouncilAdult and Children's LeukaemiaWork2ing Parties [J].Blood,1998,92:2322-2333.
80 Stone RM, ODonnellMR, SekeresMA. Acute myeloid leukemia [J]. Hematology, 2004,9:98-117.
81 SlovakML, Kopecky KJ, Cassileth PA, et al.Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:a Southwest Oncology Group/Eastern Cooperative Oncology Group Study [J].Blood,2000,96:4075-4083.
82 SanzMA, Martin G, GonzalezM, et al.Risk-adapted treamtment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:a multicenter study by the PETHEMA group [J]. Blood, 2004,103:1237-1243.
83 Rowe JM,Neuberg D,FriedenbergW, et al. A phase 3 study of three induction regimens and of p riming with GM2CSF in older adultswith acutemyeloid leukemia:a trial by the Eastem Cooperative Oncology Group [J].Blood, 2004,103:479-485.
84 Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patientswith acute myeloid leukemia is not imp roved with mitoxantrone and etoposide compared to cytarabine and daunorubicin:a SouthwestOncology Group study[J]. Blood,2002,100: 3869-3876.
85 Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group [J].N Engl J Med,1994,331:896-903.
86 Meloni G, Diverio D, VignettiM, et al. Autologous bone marrow transp lantation for acute promyelocytic leukemia in second remission:prognostic relevance of pretransp lantminimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene [J]. Blood,1997,90:1321-1325.
87 Linker CA, Ries CA, Damon LE, et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission[J]. Biol BloodMarrow Transplant,2000,6:50-57.
88 Suciu S, Mandelli F, de-Witte T, et al.Allogeneic compared with autologous stem cell transp lantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first comp lete remission (CR1):an intention-to-treat analysis of the EORTC/GIMEMAAML210 trial [J]. Blood,2003,102:1232-1240.
89 Zittoun RA, Mandelli F, Willemze R, et al.Autologous or allo-geneic bone marrow transp lantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Group s[J]. N Engl J Med, 1995,332:217-223.
90 Cornelissen JJ, Lowenberg B.Role of allogeneic stem cell transplantation on current treatment of acute myeloid leukemia[J]. Hematology,2005,10:151-155.
91 Sievers EL, Larson RA, Stadtmauer EA, et al.Efficacy and safety of gemtuzumab ozogamicin in patientswith CD332positive acute myeloid leukemia in first relapse [J]. J Clin On-col,.2001,19:3244-3254.
92 Amadori S, Suciu S, Stasi R, Willemze R, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and olderwith acutemyeloid leukemia:final results of AML215B, a phase-study of the European Organisation for Research and Treatment of Cancer and Gruppo ItalianoMalattie Ematologiche dell'Adulto Leukemia Groups [J]. Leukemia,2005,19:1768-1773.
93 KellWJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia [J]. Blood,2003,102:4277-4283.
94 沈志祥主编.难治性血液系统疾病[M].上海：上海科学技术出版社.2007：135-161.
95 Nikanfar A.Asvadi I, VN(?)J. Mitoxantrone plus cytarabine versus daunorubicin plus cytaxabine as induetion therapy for previously untreated adult patients with acute myeloid leukemia[J]. Pakistan Journal of Medical Sciences.2007.23:909-912
96 Preisler HD, Davis RB, Kirshner J, Dupre E, Richards FM, Hoagland HC et al. Comparison of three remission induction regimens and two post induction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood 1987; 69:1441-1449.
97 Cooper T, Agm M, Nowak B, at al. Biochemical modulation Of eytarabine triphosphate by elofarabinelJ]. Cancer Chemother Phannaeol,2005.55: 361-368.
98 Mustn P. Ferrara F.Clofarabine:in search of combinations for the treatment of patients with Mgh-risk acute myeloid leukemia[J].Caner2008: 1995-1998.
99 王千山等.30例大剂量阿糖胞苷化疗毒副作用的临床观察.药物与临床,2006,3(3)：8.
100 周爱萍,王奇璐.抗肿瘤药物对消化系统不良反应及其防治[J].实用肿瘤杂志,2002,17(2)：792811
101 张之南,沈悌.《血液病诊断及疗效标准(第三版)》.北京：科学技术出版社.2007.1.
102 郑筱萸.《中药新药临床研究指导原则》.北京：中国医药科技出版社.2002.4.
103 陈灏珠.《实用内科学》12版.北京：人民卫生出版社.2005.5.
104 楼金星等.强化治疗对急性早幼粒细胞白血病长期生存的影响.实用医学杂志,2007,23(21)：3389-3391.
105 吴光启等.米托蒽醌联合阿糖胞苷治疗急性粒细胞白血病36例疗效观察.中国煤炭工业医学杂志,2001,4(6).458-459.
106 郑君议等.米托蒽醌联合阿糖胞苷诱导治疗成人初治急性髓细胞性白血病疗效分析.重庆医学,2005,34(9)：1301-1304.
107 夏学鸣等.米托蒽醌联合阿糖胞苷方案治疗急性非淋巴细胞白血病52例疗效观察.江苏医药,2001,27(4)：309.
108 李梅君等.米托蒽醌和阿糖胞苷方案治疗急性非淋巴细胞白血病30例.医学综述,2009,15(18)：2867-2868.
109 李静等.MA与HDA方案治疗急性髓细胞白血病的近期疗效比较.安徽医学,2003,24(6)：57-58.
110 王璇等.MA与DA方案诱导缓解急性非淋巴细胞白血病的临床观察.中国现代医学杂志,2008,18(14)：2072-2077.
111 秦彦等.MA与DA方案诱导缓解急性单核细胞白血病的疗效比较.山西医药杂志,2009,38(8)：743-745.
112 周凡等.MA和DA方案治疗急性髓系白血病疗效对比分析.中国误诊学杂志,2005,5(3)：512-513.
113 宋东晓.MA和DA方案治疗急性非淋巴细胞白血病疗效比较.山东医药,2002,42(17)：23-24.
114 郭新红等.MA和DA方案治疗初治急性非淋巴细胞白血病的疗效分析.新疆医学,2006,36(2)：89-90.
115 艾丽梅等.MA和DA方案治疗成人急性髓细胞性白血病疗效观察.中国医药导 报,2007,4(3)：32-33.
116 李碧玲等.MA和DA方案治疗成人急性髓细胞白血病疗效分析.白血病·淋巴瘤,2004,13(4)：237-238.
117 赵璐.MA和DA方案治疗成人急性髓细胞白血病疗效比较.中国医师进修杂志,2007,30(13)：63-64.
118 赖永榕等.MA方案与ID-Ara-C方案治疗难治性及复发性急性髓细胞性白血病疗效观察.临床内科杂志,1999,16(1)
119 沈益民等.MA方案与DA、HA方案治疗复发性急性白血病的比较研究.临床荟萃,1998,13(22)：1034-1035
120 罗绍凯等.DA与MA方案诱导缓解急性非淋巴细胞白血病的疗效比较.新医学,2003,34(9)：549-553.
121 高学熙等.DA和MA方案治疗急性髓细胞性白血病疗效比较.白血病,1997,7(3)：165-166.
122 严峰.DA-MA序贯疗法治疗累及单核细胞的急性白血病疗效观察.白血病·淋巴瘤,2004,13(2)：109-110.
123 姜红,张秋业,黄芪对新生儿脐血Thl/Th2功能平衡的影响.中华围产医学杂志,2003,6(4)：225
124 贾泰元,党参对鼠J774巨噬细胞吞噬活性的增强效应.时珍国医国药,2000,11(9)：769.
125 雷载权,中药学.上海科学出版社,1995：132-311.
126 彭新国,邱世翠,李彩玉,白术对小鼠免疫功能影响的实验研究.时珍国医国药,2001,12(5)：396.
127 李佩文.中西医临床肿瘤学.北京：中国中医药出版社,1996.12.